Cargando…

Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF

BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phenotype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pulmo...

Descripción completa

Detalles Bibliográficos
Autores principales: Demirdöğen, Ezgi, Görek Dilektaşlı, Asli, Acet Öztürk, Nilüfer Aylin, Yeşilbursa, Dilek, Budak, Ferah, Öztürk, Alper, Coşkun, Funda, Ursavaş, Ahmet, Özkaya, Güven, Karadağ, Mehmet, Uzaslan, Esra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798338/
https://www.ncbi.nlm.nih.gov/pubmed/36533605
http://dx.doi.org/10.36141/svdld.v39i4.11344
_version_ 1784860887771774976
author Demirdöğen, Ezgi
Görek Dilektaşlı, Asli
Acet Öztürk, Nilüfer Aylin
Yeşilbursa, Dilek
Budak, Ferah
Öztürk, Alper
Coşkun, Funda
Ursavaş, Ahmet
Özkaya, Güven
Karadağ, Mehmet
Uzaslan, Esra
author_facet Demirdöğen, Ezgi
Görek Dilektaşlı, Asli
Acet Öztürk, Nilüfer Aylin
Yeşilbursa, Dilek
Budak, Ferah
Öztürk, Alper
Coşkun, Funda
Ursavaş, Ahmet
Özkaya, Güven
Karadağ, Mehmet
Uzaslan, Esra
author_sort Demirdöğen, Ezgi
collection PubMed
description BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phenotype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pulmonary fibrosis) patients. METHODS: Patients diagnosed with ‘CPFE’ and ‘IPF’ were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. RESULTS: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ± 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respectively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. CONCLUSIONS: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.
format Online
Article
Text
id pubmed-9798338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-97983382023-01-06 Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF Demirdöğen, Ezgi Görek Dilektaşlı, Asli Acet Öztürk, Nilüfer Aylin Yeşilbursa, Dilek Budak, Ferah Öztürk, Alper Coşkun, Funda Ursavaş, Ahmet Özkaya, Güven Karadağ, Mehmet Uzaslan, Esra Sarcoidosis Vasc Diffuse Lung Dis Original Article: Clinical Research BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phenotype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pulmonary fibrosis) patients. METHODS: Patients diagnosed with ‘CPFE’ and ‘IPF’ were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. RESULTS: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ± 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respectively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. CONCLUSIONS: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases. Mattioli 1885 2022 2022-12-19 /pmc/articles/PMC9798338/ /pubmed/36533605 http://dx.doi.org/10.36141/svdld.v39i4.11344 Text en Copyright: © 2021 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Original Article: Clinical Research
Demirdöğen, Ezgi
Görek Dilektaşlı, Asli
Acet Öztürk, Nilüfer Aylin
Yeşilbursa, Dilek
Budak, Ferah
Öztürk, Alper
Coşkun, Funda
Ursavaş, Ahmet
Özkaya, Güven
Karadağ, Mehmet
Uzaslan, Esra
Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title_full Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title_fullStr Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title_full_unstemmed Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title_short Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
title_sort serum krebs von den lungen-6: promising biomarker to differentiate cpfe from ipf
topic Original Article: Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798338/
https://www.ncbi.nlm.nih.gov/pubmed/36533605
http://dx.doi.org/10.36141/svdld.v39i4.11344
work_keys_str_mv AT demirdogenezgi serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT gorekdilektaslıasli serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT acetozturkniluferaylin serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT yesilbursadilek serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT budakferah serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT ozturkalper serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT coskunfunda serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT ursavasahmet serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT ozkayaguven serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT karadagmehmet serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf
AT uzaslanesra serumkrebsvondenlungen6promisingbiomarkertodifferentiatecpfefromipf